Monday’s news of the U.S. Food and Drug Administration’s change of heart on Sarepta Therapeutics’ potential drug for Duchenne muscular dystrophy has amplified calls for CEO Chris Garabedian’s resignation.
Notably, Forbes biotech writer Matthew Herper wrote a piece earlier this week arguing that the Cambridge biotech needs someone more experienced with the inner workings of the FDA at its helm. For the past two days, Twitter has been filled with chatter from investors saying Garabedian, who took over the company in 2011, hasn’t been transparent enough with the FDA’s guidance on how it would consider approval of the drug, eteplirsen, or questioning his competence.
Hey, check out all the research scientist jobs. Post your resume today!
